Supplementary Figures 1 - 7 from Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency

Abstract

<p>PDF file - 6330KB, Schematic representation of the recombinant vesicular stomatitis virus (VSV) genomes and its replication potential (S1). rVSV(GP) administration i.c. is associated with marginal inflammation (S2). rVSV(GP) tissue distribution after systemic application is almost consistent with rVSV (S3). rVSV(GP) is comparable to rVSV with regard to its in vitro antitumour efficacy (S4). Replication fitness of rVSV(GP) vs. rVSV in glioma cells (S5). Intratumoural virus administration in s.c. G62 human glioblastoma xenografts leads to productive infection and massive viral burst (S6). U87rfp tumour relapse was not due to OV therapy resistance (S7).</p>